Article · 30 Dec 2024
Conference abstract
The hunt for biomarkers of the earliest stage breast cancer progression
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Ductal carcinoma in situ (DCIS) of the breast is a non-invasive proliferative tumour. This so-called stage “0” breast cancer has not yet developed or may never develop to advanced cancer. With the use of screening mammography worldwide, DCIS has become a clinical challenge due to its increasing incidence and uncertain prognosis. Presently, an indolent DCIS cannot be distinguished from a progressive tumour, making the appropriate treatment for DCIS patients, a major clinical dilemma. Researchers hope to identify predictive biomarkers (BM) that can forecast the pro-malignant potential of DCIS to guide the treatment. Although a variety of high throughput transcriptomics technologies have been employed for the molecular analysis of DCIS, predictive biomarker (BM) able to determine beforehand which patients might have progressive disease were not determined. The employment of new technologies and alternative approaches are important next steps. We have been developing methodology to delve into tissue’s protein BM that in advance of the treatment have determined the likelihood that DCIS becomes invasive, as opposed to remaining indolent tumour. We assumed that DCIS with synchronous microinvasive carcinoma (T1mic) represents the earliest stage 1 breast cancer, because invasion increases the likelihood of metastasis. Using our novel imaging method for archival tissue analysis, we performed quantitative protein profiling on 211 human breast tissues: 42 histologically normal, 71 cancer in situ (including 11 T1mic) and 98 invasive carcinomas. In this pilot study, we identified Vav2 oncoprotein as a promising BM of progressive DCIS. We found that DCIS with high Vav2 protein were more than twice as likely to progress to invasive cancer as DCIS with low Vav2 protein (odds ratio, 2.42; p=o.008). Furthermore, measurements of Vav2 revealed previously unidentified discriminating power of Vav2 to predict the existence of invasion synchronous with DCIS. Our further studies are underway to characterise additional BM.
Keywords
Subjects
Pathology & Lab MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Biomarkers Journal.
Article · 30 Dec 2024
Genomic Biomarkers: Bridging the Gap between Genetics and Precision Medicine
Article · 30 Dec 2024
Cryogenic Markers: Advancing Low Temperature Science and Applications
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalBiomarkers Journal
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Marina Guvakova”